SLC1A7 mutation is a cause of the autosomal dominant form of Parkinson’s disease
Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease
Objective: To generate and characterize induced pluripotent stem cells (iPSCs)-derived in vitro cellular models of Autosomal Recessive Juvenile Parkinsonism (ARJP) carrying Park2 mutations with a…Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide
Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…mGlu3 receptors in Parkinson’s disease as a candidate target for neuroprotective therapy: evidence from preclinical studies to human genetic.
Objective: In a toxicological model of mouse parkinsonism through chronic injection of MPTP, we examined whether the presence or absence of mGlu3 receptors affected neurodegeneration…The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset
Objective: To determine the effect of positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset using a low…Administration of the mGlu2 positive allosteric modulator BINA as monotherapy improves parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of selective metabotropic glutamate type 2 (mGlu2) receptor activation on parkinsonism as monotherapy in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset compared to…Mutational effects of LRRK2 I1371V in astrocytes derived from patient specific iPSCs
Objective: To identify the LRRK2 I1371V mutational effects on astroglial biology involving glutamate metabolism and glutathione machinery. Background: The underlying cause of most of the familial…Synaptic Zn2+ Contribution to Parkinson’s Disease Pathophysiology: Pharmacological & Genetic Studies in Preclinical Mouse Models
Objective: The potential involvement of synaptic Zn2+ in development of Parkinson’s disease (PD) motor symptoms and dopaminergic neurodegeneration was investigated. Background: The progressive degeneration of…Long-term effect of safinamide on primary motor cortex excitability and plasticity in Parkinson’s disease: a TMS study
Objective: To examine the long-term effect of chronic treatment with safinamide 100 mg/day on specific Transcranial Magnetic Stimulation (TMS) measures of primary motor cortex (M1)…Induction of Parkinsonian-like changes via targeted down-regulation of astrocytic glutamate transporter GLT-1 in the striatum
Objective: The aim was to explore the function and mechanism of astrocytic GLT-1 in PD-like changes. Background: Numerous researches suggest decreased expression of glutamate transporter-1…
- 1
- 2
- 3
- 4
- Next Page »